SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial.
Saved in:
| Title: | SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial. |
|---|---|
| Authors: | Tøndel C; Haukeland University Hospital, Department of Pediatrics and University of Bergen, Department of Clinical Science, Bergen, Norway., Jenum S; Oslo University Hospital, Department of Infectious Diseases, Oslo, Norway., Tonby K; Oslo University Hospital, Department of Infectious Diseases, Oslo, Norway; University of Oslo, Institute of Clinical Medicine, Oslo, Norway., Christensen EE; Oslo University Hospital, Department of Infectious Diseases, Oslo, Norway; University of Oslo, Institute of Clinical Medicine, Oslo, Norway., Cox RJ; University of Bergen, Department of Clinical Science, The Influenza Center, Bergen, Norway; Haukeland University Hospital, Department of Microbiology, Bergen, Norway., Onyango TB; University of Bergen, Department of Clinical Science, The Influenza Center, Bergen, Norway; Haukeland University Hospital, Department of Microbiology, Bergen, Norway., Skeie LG; Oslo University Hospital, Department of Infectious Diseases, Oslo, Norway., Robins H; Adaptive Biotechnologies, Seattle, WA, USA., Klinger M; Adaptive Biotechnologies, Seattle, WA, USA., Banbury B; Adaptive Biotechnologies, Seattle, WA, USA., Bello T; Adaptive Biotechnologies, Seattle, WA, USA., Osborne EJ; Adaptive Biotechnologies, Seattle, WA, USA., Jørgensen MJ; Nykode Therapeutics ASA, Oslo, Norway. Electronic address: Mjjorgensen@nykode.com., Pourpe S; Nykode Therapeutics ASA, Oslo, Norway., Leikfoss IS; Nykode Therapeutics ASA, Oslo, Norway., Jürgens T; Nykode Therapeutics ASA, Oslo, Norway., Wold H; Nykode Therapeutics ASA, Oslo, Norway., Torhaug S; Nykode Therapeutics ASA, Oslo, Norway., Makvandi-Nejad S; Nykode Therapeutics ASA, Oslo, Norway., Edo-Matas D; Nykode Therapeutics ASA, Oslo, Norway., Schjetne K; Nykode Therapeutics ASA, Oslo, Norway., Fredriksen AB; Nykode Therapeutics ASA, Oslo, Norway., Norheim G; Nykode Therapeutics ASA, Oslo, Norway., Dyrhol-Riise AM; Oslo University Hospital, Department of Infectious Diseases, Oslo, Norway; University of Oslo, Institute of Clinical Medicine, Oslo, Norway. |
| Source: | Vaccine [Vaccine] 2026 Mar 07; Vol. 75, pp. 128290. Date of Electronic Publication: 2026 Feb 01. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I |
| Journal Info: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41628524 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Tøndel+C%22">Tøndel C</searchLink>; Haukeland University Hospital, Department of Pediatrics and University of Bergen, Department of Clinical Science, Bergen, Norway.<br /><searchLink fieldCode="AU" term="%22Jenum+S%22">Jenum S</searchLink>; Oslo University Hospital, Department of Infectious Diseases, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Tonby+K%22">Tonby K</searchLink>; Oslo University Hospital, Department of Infectious Diseases, Oslo, Norway; University of Oslo, Institute of Clinical Medicine, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Christensen+EE%22">Christensen EE</searchLink>; Oslo University Hospital, Department of Infectious Diseases, Oslo, Norway; University of Oslo, Institute of Clinical Medicine, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Cox+RJ%22">Cox RJ</searchLink>; University of Bergen, Department of Clinical Science, The Influenza Center, Bergen, Norway; Haukeland University Hospital, Department of Microbiology, Bergen, Norway.<br /><searchLink fieldCode="AU" term="%22Onyango+TB%22">Onyango TB</searchLink>; University of Bergen, Department of Clinical Science, The Influenza Center, Bergen, Norway; Haukeland University Hospital, Department of Microbiology, Bergen, Norway.<br /><searchLink fieldCode="AU" term="%22Skeie+LG%22">Skeie LG</searchLink>; Oslo University Hospital, Department of Infectious Diseases, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Robins+H%22">Robins H</searchLink>; Adaptive Biotechnologies, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Klinger+M%22">Klinger M</searchLink>; Adaptive Biotechnologies, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Banbury+B%22">Banbury B</searchLink>; Adaptive Biotechnologies, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Bello+T%22">Bello T</searchLink>; Adaptive Biotechnologies, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Osborne+EJ%22">Osborne EJ</searchLink>; Adaptive Biotechnologies, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Jørgensen+MJ%22">Jørgensen MJ</searchLink>; Nykode Therapeutics ASA, Oslo, Norway. Electronic address: Mjjorgensen@nykode.com.<br /><searchLink fieldCode="AU" term="%22Pourpe+S%22">Pourpe S</searchLink>; Nykode Therapeutics ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Leikfoss+IS%22">Leikfoss IS</searchLink>; Nykode Therapeutics ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Jürgens+T%22">Jürgens T</searchLink>; Nykode Therapeutics ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Wold+H%22">Wold H</searchLink>; Nykode Therapeutics ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Torhaug+S%22">Torhaug S</searchLink>; Nykode Therapeutics ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Makvandi-Nejad+S%22">Makvandi-Nejad S</searchLink>; Nykode Therapeutics ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Edo-Matas+D%22">Edo-Matas D</searchLink>; Nykode Therapeutics ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Schjetne+K%22">Schjetne K</searchLink>; Nykode Therapeutics ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Fredriksen+AB%22">Fredriksen AB</searchLink>; Nykode Therapeutics ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Norheim+G%22">Norheim G</searchLink>; Nykode Therapeutics ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Dyrhol-Riise+AM%22">Dyrhol-Riise AM</searchLink>; Oslo University Hospital, Department of Infectious Diseases, Oslo, Norway; University of Oslo, Institute of Clinical Medicine, Oslo, Norway. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228406899%22">Vaccine</searchLink> [Vaccine] 2026 Mar 07; Vol. 75, pp. 128290. <i>Date of Electronic Publication: </i>2026 Feb 01. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8406899 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-2518 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220264410X%22">0264410X </searchLink><i>NLM ISO Abbreviation: </i>Vaccine <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41628524 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.vaccine.2026.128290 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 128290 Titles: – TitleFull: SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Tøndel C – PersonEntity: Name: NameFull: Jenum S – PersonEntity: Name: NameFull: Tonby K – PersonEntity: Name: NameFull: Christensen EE – PersonEntity: Name: NameFull: Cox RJ – PersonEntity: Name: NameFull: Onyango TB – PersonEntity: Name: NameFull: Skeie LG – PersonEntity: Name: NameFull: Robins H – PersonEntity: Name: NameFull: Klinger M – PersonEntity: Name: NameFull: Banbury B – PersonEntity: Name: NameFull: Bello T – PersonEntity: Name: NameFull: Osborne EJ – PersonEntity: Name: NameFull: Jørgensen MJ – PersonEntity: Name: NameFull: Pourpe S – PersonEntity: Name: NameFull: Leikfoss IS – PersonEntity: Name: NameFull: Jürgens T – PersonEntity: Name: NameFull: Wold H – PersonEntity: Name: NameFull: Torhaug S – PersonEntity: Name: NameFull: Makvandi-Nejad S – PersonEntity: Name: NameFull: Edo-Matas D – PersonEntity: Name: NameFull: Schjetne K – PersonEntity: Name: NameFull: Fredriksen AB – PersonEntity: Name: NameFull: Norheim G – PersonEntity: Name: NameFull: Dyrhol-Riise AM IsPartOfRelationships: – BibEntity: Dates: – D: 07 M: 03 Text: 2026 Mar 07 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1873-2518 Numbering: – Type: volume Value: 75 Titles: – TitleFull: Vaccine Type: main |
| ResultId | 1 |